Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
XC

NASDAQ · XCUR

Exicure, Inc.

Healthcare · Biotechnology

$1.01

Up+$0.08 (+8.04%)

Updated Nov 2, 2026, 9:05 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.07M
P/E ratio
-4.91
Dividend yield
0.00%
52-week range
$0.88 – $9.48
Volume
29.57K
Avg. volume
653.33K

Price performance · XCUR

XCUR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

XCUR closed at $1.01 after 20 trading sessions, down 5.61% for the selected period.

Last close
$1.01
Period change
-5.61%
Period low
$0.93
Period high
$1.21
Daily close
View OHLC price history
XCUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.9438$1.06$0.9438$1.0129.57K
Oct 29, 2026$1.05$1.09$0.8752$0.934841.44K
Oct 28, 2026$1.08$1.13$1.01$1.016525.24K
Oct 27, 2026$1.10$1.10$1.03$1.0712.33K
Oct 26, 2026$1.06$1.09$1.02$1.0936.11K
Oct 23, 2026$1.10$1.14$1.04$1.0561.29K
Oct 22, 2026$1.15$1.28$1.0801$1.13439.97K
Oct 21, 2026$0.9841$1.05$0.9705$1.0140.66K
Oct 20, 2026$1.11$1.11$0.9901$0.998747.86K
Oct 19, 2026$1.12$1.30$1.0294$1.0369.15K
Oct 16, 2026$1.2144$1.2144$1.08$1.1238.53K
Oct 15, 2026$1.21$1.24$1.10$1.1220.66K
Oct 14, 2026$1.16$1.26$1.16$1.2128.35K
Oct 13, 2026$1.12$1.21$1.09$1.1529.66K
Oct 12, 2026$1.09$1.10$1.06$1.0915.3K
Oct 9, 2026$0.95$1.10$0.936$1.05316.53K
Oct 8, 2026$0.99$1.05$0.99$1.0014.84K
Oct 7, 2026$1.04$1.04$1.00$1.029.23K
Oct 6, 2026$1.11$1.11$1.0701$1.087.34K
Oct 5, 2026$1.14$1.19$1.07$1.0718.15K

Latest XCUR news

The latest Smart Investors Daily articles mentioning XCUR.

Stock researchCompany · Overview

XCUR research

Overview

Company profile and research snapshot.

Company profile

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.00
Implied upside
—
Analysts
6
XCUR recent ratings
DateFirmRatingTarget
Aug 16, 2022Chardan CapitalNeutral—
Dec 13, 2021Chardan CapitalNeutral—
Nov 23, 2021Chardan CapitalBuy—
May 17, 2021HC Wainwright & Co.Buy—
Dec 18, 2020BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed, on June 5, 2026, Nasdaq notified the Company that it did not satisfy Nasdaq Listing Rule 5550(b)

Yahoo · Aug 3, 2026

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By